Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Deidre McSweeny-Tyson

Pediatric Endocrinology Florence, SC Medical Doctor

NPI 1225132665 CMS profile 282320

101 William H Johnson St Ste 420, Florence, SC 29506

Open in the dashboard

General payments

$3,470

177 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Deidre McSweeny-Tyson of Florence, SC is reported in the CMS Open Payments database as having received $3,470 across 177 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 71st percentile of Pediatric Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $550 27
2022 General $1,367 64
2021 General $1,082 57
2020 General $444 28
2019 General $27 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Deidre McSweeny-Tyson
  • Pediatric Endocrinology median
  • Middle half of Pediatric Endocrinology
  • National median

In program year 2025, general payments to Deidre McSweeny-Tyson were reported at $0. Among 971 Pediatric Endocrinology profiles paid that year, the median was $293 and the middle half received between $106 and $1,640.

Show as a table
Year Deidre McSweeny-Tyson Pediatric Endocrinology median Middle half National median
2019 $27 $196 $68–$845 $163
2020 $444 $124 $37–$722 $114
2021 $1,082 $134 $35–$691 $132
2022 $1,367 $177 $47–$726 $149
2023 $550 $236 $75–$887 $160
2024 $0 $259 $91–$979 $164
2025 $0 $293 $106–$1,640 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. AbbVie, Inc. $616 33 payments
  2. Abbott Laboratories $456 20 payments
  3. Insulet Corporation $402 20 payments
  4. Novo Nordisk Inc $242 10 payments
  5. Lilly USA, LLC $240 15 payments
  6. Arbor Pharmaceuticals, Inc. $212 12 payments
  7. Xeris Pharmaceuticals, Inc. $201 12 payments
  8. Horizon Therapeutics plc $153 4 payments
  9. Rhythm Pharmaceuticals, Inc. $133 5 payments
  10. Zealand Pharma US, Inc. $117 6 payments
  11. Other $697 40 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $3,470 177 payments
Products named General payments · program years 2019–2023
  1. LUPRON DEPOT $469 24 payments
  2. Omnipod $375 18 payments
  3. Triptodur $234 13 payments
  4. BAQSIMI $214 13 payments
  5. FreeStyle Libre 2 $186 12 payments
  6. GVOKE PFS $165 10 payments
  7. TEPEZZA $153 4 payments
  8. Norditropin $152 8 payments
  9. FreeStyle Libre 3 $147 6 payments
  10. LYUMJEV $130 7 payments
  11. Other $1,147 63 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

177 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Endocrinology in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record